Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Safety and Pharmacokinetics of ODM-209 [Phase 1, Phase 2]
Phase 1/2 trial update on safety and pharmacokinetics of ODM-209 for metastatic prostate cancer and advanced/metastatic breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations [Phase 2]
Phase 2 trial evaluating immunotherapy in patients with metastatic cancers harboring CDK12 mutations has completed and results were posted.
-
CLINICAL_TRIALS trial_result · 2024-01-24Clinical Trial Update: Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors [Phase 1, Phase 2]
Clinical trial update on TT-00420 tablets with toripalimab for advanced urological tumors (Phase 1/2) with conditions including clear cell r…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC [Phase 3]
Phase 3 trial evaluating talazoparib in combination with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate …
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer [Phase 3]
Phase 3 trial update for TAVT-45 (Abiraterone Acetate) granules in metastatic prostate cancer patients has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC [Phase 2]
Phase 2 clinical trial update reporting on the safety and tolerability of GT0918 in patients with metastatic hormone-sensitive and castratio…
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus enzalutamide versus placebo plus enzalutamide in metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus enzalutamide versus placebo plus enzalutamide in metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating niraparib in combination therapies for metastatic castration-resistant prostate cancer; the study is active/not rec…
-
FDA approval · 2023-11-16FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc., updating the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial evaluating PSCA-CAR T cells in PSCA-positive metastatic castration-resistant prostate cancer; study is active not rec…
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer [Phase 3]
Phase 3 trial evaluating niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for meta…
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer [Phase 3]
Phase 3 trial of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in metastatic castration-resist…
-
CLINICAL_TRIALS trial_result · 2023-10-03Clinical Trial Update: COMbination of Bipolar Androgen Therapy and Nivolumab [Phase 2]
Phase 2 trial evaluating the combination of Bipolar Androgen Therapy with Nivolumab in prostate cancer has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 3]
Phase 3 trial update evaluating masitinib in combination with docetaxel for metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS withdrawal · 2023-09-14Clinical Trial Update: Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC [Phase 3]
Phase 3 trial investigating darolutamide with radium-223 or placebo in metastatic castration-resistant prostate cancer was withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-09-07Clinical Trial Update: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating durvalumab with or without tremelimumab in metastatic castration-resistant prostate cancer; results have been poste…
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency [Phase 3]
Phase 3 trial comparing rucaparib to physician's choice in metastatic castration-resistant prostate cancer with homologous recombination def…
-
FDA approval · 2023-08-11FDA Approved: AKEEGA — Original Application (Janssen Biotech, Inc.)
FDA approved AKEEGA, a fixed-dose combination of niraparib tosylate monohydrate and abiraterone acetate. This represents an original applica…
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. [Phase 2]
Phase 2 trial of AZD4635 combined with durvalumab, and with cabazitaxel + durvalumab, in progressive metastatic castration-resistant prostat…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) [Phase 2]
Phase 2 trial comparing darolutamide and enzalutamide in castration-resistant prostate cancer; study terminated with results posted.
-
CLINICAL_TRIALS withdrawal · 2023-08-04Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension [Phase 3]
Phase 3 trial (KEYNOTE-921) evaluating pembrolizumab with docetaxel versus placebo with docetaxel in chemotherapy-naïve metastatic castratio…
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) [Phase 1, Phase 2]
Phase 1/2 trial PRINCE evaluating PSMA-lutetium radioligand therapy combined with immune therapy in metastatic castration-resistant prostate…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]
A Phase 2 clinical trial evaluating RC48-ADC for efficacy and safety in metastatic castration-resistant prostate cancer is ongoing, with sta…
-
CLINICAL_TRIALS research · 2023-07-14Clinical Trial Update: ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update for ESK981 in metastatic castration-resistant prostate cancer shows completed status with posted results.